[Ip-health] MSF and The Union release new edition of DR-TB drugs report

Joanna Keenan-Siciliano joanna.l.keenan at gmail.com
Wed Nov 14 01:56:29 PST 2012


Médecins Sans Frontières and the International Union Against Tuberculosis
and Lung Disease have today released the second edition of DR-TB Drugs
Under the Microscope, a report examining prices, sources and issues
surrounding medicines used for treatment of drug-resistant TB (DR-TB).

Download the report here:
http://msfaccess.org/content/dr-tb-drugs-under-microscope-2nd-edition

With new, faster tools diagnosing more people than ever before, DR-TB is a
growing epidemic, requiring an immediate response on how to address the
urgent need for treatment scale up. But treatment scale up is hampered by a
number of factors, including high prices (the average regimen costs
US$4,000 - $6,000) and limited availability of quality-assured DR-TB
medicines.

DR-TB Drugs Under the Microscope also looks at recent progress in the drug
pipeline, with two completely new compounds – bedaquiline and delamanid –
due for approval soon, the first new drugs in close to half a century. How
these drugs will be used in treatment regimens – whether they’re added to
existing regimes or news ones are devised – is critical in managing DR-TB
treatment in the future. The report also looks at the issues surrounding
access for DR-TB drugs, with a focus on linezolid and clofazimine.

The second edition of DR-TB Drugs Under the Microscope can be found here:
http://msfaccess.org/content/dr-tb-drugs-under-microscope-2nd-edition


Joanna Keenan
Press Officer
Médecins Sans Frontières - Access Campaign
E: joanna.keenan[at]geneva.msf.org
T: twitter.com/joanna_keenan

msfaccess.org
twitter.com/MSF_access
facebook.com/MSFaccess



More information about the Ip-health mailing list